{"entity":{"id":"nct07819578","kind":"trial","name":"Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC","aka":[],"tldr":"A phase 2 trial of toripalimab and sacituzumab tirumotecan in lung cancer, run by Shaodong Hong, not yet recruiting.","summary":"Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC is a phase 2, interventional study registered as NCT07819578 by Shaodong Hong, with a registry enrolment figure of 30 participants, started 2026-10-01 and due to reach its primary completion in 2028-12-01. Interventions recorded: Toripalimab; Sacituzumab Tirumotecan (SKB264). Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Pathological Complete Response (pCR) Rate. Lung eligibility wording from the registry: \"* Histologically/cytologically confirmed, treatment-naive, resectable or potentially resectable NSCLC: stage II-IIIA and selected IIIB (T3N2, T4N2) per IASLC/UICC TNM 9th edition\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07819578","url":"https://clinicaltrials.gov/study/NCT07819578"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["adc","checkpoint-inhibitor"],"targets":[],"drugs":["toripalimab","sacituzumab-tirumotecan"],"companies":["kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07819578","phase":"2","setting":"A Phase II Study of Toripalimab Combined With Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer","sponsor":"Shaodong Hong","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07819578/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}